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Abstract
Background: Toll like receptors (TLR) play the central role in the recognition of pathogen
associated molecular patterns (PAMPs). Mutations in the TLR1, TLR2 and TLR4 genes may change
the ability to recognize PAMPs and cause altered responsiveness to the bacterial pathogens.
Results: The study presents association between TLR gene mutations and increased susceptibility
to Mycobacterium avium subsp. paratuberculosis (MAP) infection. Novel mutations in TLR genes
(TLR1- Ser150Gly and Val220Met; TLR2 – Phe670Leu) were statistically correlated with the
hindrance in recognition of MAP legends. This correlation was confirmed subsequently by
measuring the expression levels of cytokines (IL-4, IL-8, IL-10, IL-12 and IFN-) in the mutant and
wild type moDCs (mocyte derived dendritic cells) after challenge with MAP cell lysate or LPS.
Further in silico analysis of the TLR1 and TLR4 ectodomains (ECD) revealed the polymorphic nature
of the central ECD and irregularities in the central LRR (leucine rich repeat) motifs.
Conclusion: The most critical positions that may alter the pathogen recognition ability of TLR
were: the 9th amino acid position in LRR motif (TLR1–LRR10) and 4th residue downstream to LRR
domain (exta-LRR region of TLR4). The study describes novel mutations in the TLRs and presents
their association with the MAP infection.
Background
A conserved set of receptors called pattern-recognition
receptors has immense importance in the innate immune
system. The role of TLRs, members of mammalian pat-
tern-recognition receptors, has been elaborated in the
recent years [1-5]. They are the key components of patho-
gen recognition mechanism initiating inflammatory
responses brought about by microbes or microbial cell
components [6,7]. TLR family possesses 14 distinct mem-
bers identified so far, expressed by epithelial and endothe-
lial cells as well as leukocytes. TLRs are type-I
transmembrane receptors composed of an ectodomains, a
short transmembrane region, and an intracellular signal-
ing domain that shares homology with that of the IL-1
receptor [8]. TLR mediated cellular activation occurs fol-
lowing the recognition of specific microbial components
by the ECD [8]. These receptors act as the sensors for viral,
bacterial and fungal structures, for example, TLR3 recog-
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nizes viral dsDNA [9], TLR7 and TLR8 recognize the
ssRNA [10-12], TLR5 triggers immune signal by detecting
flagellin, and CpG DNA is the ligand for TLR9 [13,14].
Toll like receptors focused in this study, TLR1, TLR2 and
TLR4, recognize bacterial cell components. TLR2 has
shown to mediate the innate immune response to ligands
derived from Mycoplasma, Borrelia, Treponema, Chlamydia,
yeasts and parasites [15-20]. TLR2 and TLR4 are critical in
the immune response against Gram positive and negative
bacteria [21]. Indeed, TLR1 and TLR6 in association with
TLR2 (TLR1-TLR2 and TLR2-TLR6 heteromers) recognize
a variety of bacterial cell wall components [22-25].
Mutations in the coding region of human TLRs are linked
with the altered PAMP recognition ability, signal trans-
duction or innate immune activation in general [19,26-
30]. Mutations in TLR1 gene are associated with the vari-
ation in the immune response to lipopeptides [27],
increased susceptibility to invasive aspergillosis [31] or
impaired innate immune sensing of microbial cell wall
components [32]. TLR2 and TLR4 gene polymorphisms
are often linked with increased risk to infections like
tuberculosis [15,33], Mycobacterium leprae [34,35], pneu-
mococci or malaria [30,36], urinary tract infections [37]
and disease conditions like periodontitis [38], acute rheu-
matic fever [39] and Crohn's disease [40].
The aim of the study was to screen the ovine population
for the mutations in TLR1, TLR2 and TLR4 genes, and to
assess their possible association with susceptibility to
MAP.
Results
Presence of MAP in the sheep population
82 sheep (11.3%) were found to be infected with MAP
when tested with ELISA as well as IS900 based PCR. MAP
infected (n = 82) and non-infected (n = 838) sheep were
studied further for the presence of TLR mutations.
TLRs gene mutations and MAP infection
None of the earlier cited mutations in TLR2 and TLR4
(TLR2 – Pro681His, Arg677Trp, Arg753Gln, and TLR4 –
Asp299Gly, Thr399Ile) were found in the sheep popula-
tion. However, the sequence analysis revealed novel
mutations in the ovine TLR2 and TLR4 (Tables 1, 2, 3). We
found novel mutation Phe670Leu in TLR2 gene in 56
sheep infected with MAP. 25% of the subjects carrying this
mutation in heterozygous state (OR – 4.5) and 7.6% sub-
jects carrying this mutation in homozygous state (OR –
1.1) were MAP infected (Table 2). Another mutation in
TLR2 gene at the base pair 2037 (T to C) exchanging leu-
cine against proline (679th amino acid residue) was found
in 54 subjects infected with MAP. Both these mutations
are located in highly conserved region of TLR2 gene near
the known mutation Arg677Trp.
Novel mutation in TLR4 gene associated with the
increased susceptibility to MAP infection was located at
the base pair T1066C exchanging phenylalanine against
leucine (OR – 1.64). Other mutations found in TLR2 and
TLR4 genes in this study (Tables 2 and 3) had no associa-
tion with the increased susceptibility to MAP infection.
Two mutations (Ser150Gly and Val220Met) in TLR1 gene
were found in 74 subjects, of that 32 sheep (43.2%) were
infected with MAP. Both these mutations occurred simul-
taneously in all 74 subjects. Apart from these two muta-
tions we found novel mutations in TLR1 at the base pairs:
418 (A to G), 431 (A to T), 508 (T to C), 601 (A to T) and
603 (T to C) (Table 1).
TLR expression in mutant moDCs
Representative sheep (n = 6 per mutation;mutant moDCs),
not infected with MAP but carrying mutations associated
with MAP infection were included in this phase of the
study. Healthy sheep without TLR mutations (n = 6; wild
type moDCs) were targeted for TLR mRNA expression as a
Table 1: Missense mutations in the ovine TLR1
Wild type frequency Frequency of mutation in 
heterozygous state




Lys140Glu 0.997 (11.4%) 0 0.002 (0%)
431A>T Asn144Ile 0.997 (11.4%) 0 0.002 (0%)
448A>
G
Ser150Gly 0.897 (8.38%) 0 0.10 (43.2%, 9.08)1
508T>C Ser170Pro 0.997 (11.4%) 0 0.002 (0%)
517G>R Glu173 [Lys, Glu] 0.897 (8.38%) 0.10(43.2%, 9.08)0
601A>T Ile201Phe 0.997 (11.4%) 0 0.002 (0%)
603T>C Ile201Phe 0.997 (11.4%) 0 0.002 (0%)
658A>
G
Val220Met 0.897 (8.38%) 0 0.102 (43.2%, 9.08)
1 The first value in the parenthesis indicate the percentage of animals infected with MAP that carries given point mutation, the second value (bold-
italics) is the Odd's ratio (OR) indicating the possible linkage between the point mutation and increased susceptibility to MAP infection.BMC Genetics 2009, 10:21 http://www.biomedcentral.com/1471-2156/10/21
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control. We observed 3–6 fold increase in the TLRs expres-
sion in activated moDCs as compared to the non-acti-
vated control moDCs (Figure 1). However, when mutant
and wild type moDCs were challenged with LPS or MAP
whole cell lysate, the antigen dependent induction of
TLRs was not observed (P > 0.05; Figure 1). Expression of
-actin was unchanged throughout the TLR mRNA expres-
sion experiments (data not shown).
TLR mutations and cytokine mRNA production
IFN-, IL-10 and IL-12 were abundantly expressed
cytokines in the wild type moDCs when challenged with
LPS and MAP whole cell lysate. The cytokines expression,
except IL-4, in challenged wild type moDCs was 6 to 9
fold higher than in non-challenged moDCs (Figure 2). In
general, MAP cell lysate caused higher cytokine response
in the moDCs than LPS. Expression of IL-8 was lower than
other abundantly expressed ILs, whereas IL-4 was neither
detected in ovine wild type nor in mutant moDCs (Figure
2).
Table 2: Missense mutations in the ovine TLR2
Wild type frequency Frequency of mutation in 
heterozygous state
Frequency of mutation in 
homozygous state
1985A>W Glu662 [Glu, Val] 0.94 (21%) 0.06 (4.7%) 0
2008A>Y Phe670 [Leu, Phe] 0.55 (6.5%) 0.25 (25%, 4.5) 0.20 (7.6%, 1.1)1
2012A>M Lys671 [Asn, Thr] 0.99 (11.4%) 0.01 (0%) 0
2013G>T Lys671 [Asn, Thr] 0.99 (11.4%) 0 0.01 (0%)
2028G>S Lys676 [Asn, Lys] 0.99 (11.4%) 0.01 (0%) 0
2037T>Y Leu679Phe 0.57 (6.3%) 0.35 (19.9%, 2.01) 0.08 (10.3%, 1.36)
2038G>A Val680Ile 0.998(11.4%) 0 0.002 (0%)
2040C>T Val680Ile 0.998(11.4%) 0 0.002 (0%)
2090G>R Arg697 [His, Arg] 0.997 (12.9%) 0.001 (0%) 0.003 (0%)
2111C>y Ser704 [Ser, Leu] 0.998 (11.4%) 0.002 (0%) 0
2117G>A Ser706Asn 0.995 (11.4%) 0 0.005 (0%)
2126G>A Arg709Lys 0.997 (11.4%) 0 0.003 (0%)
2233G>R Val745 [Ile, Val] 0.995 (11.4%) 0.001 (0%) 0.004 (0%)
2276G>A Arg759Lys 0.995 (11.4%) 0 0.005 (0%)
2296G>A Val766Thr 0.998 (11.4%) 0 0.002 (0%)
2297T>C Val766Thr 0.998 (11.4%) 0 0.002 (0%)
1 The first value in the parenthesis indicate the percentage of animals infected with MAP that carries given point mutation, the second value (bold-
italics) is the Odd's ratio (OR) indicating the possible linkage between the point mutation and increased susceptibility to MAP infection.
Table 3: Missense mutations in the ovine TLR4
Wild type frequency Frequency of mutation in 
heterozygous state
Frequency of mutation in 
homozygous state
881G>R Ser294 [Ser, Asn] 0.84 (12.6%) 0.14 (5.7%) 0.02 (0%)
883A>R Lys295 [Lys, Glu] 0.84 (12.6%) 0.14 (5.7%) 0.02 (0%)
892T>Y Trp298 [Trp, Arg] 0.84 (12.6%) 0.14 (5.7%) 0.02 (0%)
934G>A Val312Met 0.998 (11.4%) 0 0.002 (0%)
955T>C Ser319Pro 0.998 (11.4%) 0 0.002 (0%)
1029T>K Asp343 [Glu, Asp] 0.993 (11.4%) 0.007 (0%) 0
1032G>S Lys344 [Asn, Lys] 0.87 (12.6%) 0.12 (3.5%) 0.012 (0%)
1045A>
G
Lys349Glu 0.998 (11.4%) 0 0.002 (0%)
1052G>R Arg351 [His, Arg] 0.87 (12.3%) 0.12 (5.8%) 0.012 (0%)
1066T>Y Phe356 [Leu, Phe] 0.36 (14.3%) 0.52 (8.2%) 0.12 (16.4%, 1.64)1
1088A>R Asp363 [Asp, Gly] 0.84 (12.5%) 0.14 (5.7%) 0.02 (0%)
1091T>Y Val364 [Val, Ala] 0.84 (12.5%) 0.14 (5.7%) 0.02 (0%)
1097C>S Thr366 [Thr, Ser] 0.84 (12.5%) 0.14 (5.7%) 0.02 (0%)
1166G>S Ser389 [Thr, Ser] 0.998 (11.4%) 0.001 (0%) 0
1183G>K Asp395 [Asp, Tyr] 0.84 (12.5%) 0.14 (6%) 0.002 (0%)
1 The first value in the parenthesis indicate the percentage of animals infected with MAP that carries given point mutation, the second value (bold-
italics) is the Odd's ratio (OR) indicating the possible linkage between the point mutation and increased susceptibility to MAP infection.BMC Genetics 2009, 10:21 http://www.biomedcentral.com/1471-2156/10/21
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Expression of IL-10 in the challenged TLR1 mutant
(Gly150, Met220) moDCs was significantly lower (P <
0.05; Figure 2 panel C) than in the challenged wild type
moDCs. This cytokine was also under expressed in the
mutant moDCs carrying TLR2 Leu670 mutation (Figure 2
panel C). Another two cytokines, IFN- and IL-12, were
under expressed in the mutant moDCs carrying TLR1
(Gly150, Met220) and TLR2 (Leu670) mutations com-
pared with the wild type moDCs (Figure 2 panel D and E).
Interestingly IL-8 mRNA expression was unchanged in
TLR1 mutant moDCs, but significantly lowered (P < 0.05,
Figure 2 panel B) in TLR2 Leu670 moDCs. No altered
cytokine expression was noticed in the challenged moDCs
carrying TLR2 Phe679 and TLR4 Leu356 mutations (Fig-
ure 2).
TLR1 and TLR4 LRR motifs: In silico analysis
TLR gene family is conservative and show certain homol-
ogy between human and ovine TLR genes (TLR1 ~75%,
TLR2 ~82 and TLR4 ~80). The central core of regular LRR
motif is LxxLxLxxNxL, wherein 'x' is any amino acid, 'L' is
Leu, Ile, Val or Phe, and 'N' is Asn, Thr, Ser or Cys. Certain
irregularities were observed within the LRR motifs of TLR1
(LRR8 and LRR11) and TLR4 (LRR13 and LRR14) (Figure
3 panel A and B). A central part of ovine TLR1 ectodomain
(LRR10) was prone to missense mutations and more
irregular than other LRRs. TLR1 mutations Gly150 and
Met220, causing hyporesponsiveness to MAP infection,
were located within the extra-LRR region and intra-LRR
motif respectively (Figure 3 panel A). Met220 mutation
was found in LRR10 motif at the 9th amino acid position
(LxxLxLxxN9thxL).
We also present LRR motif structure of TLR4 ECD span-
ning earlier described Asp299Gly and Thr399Ile muta-
tions. Both mutations were found in extra LRR region
(Figure 3 panel B) in human TLR4. In the sheep popula-
tion TLR4 Asp299Gly and Thr399Ile mutations were
absent; however, the amino acid position 299 was occu-
pied by asparagine and 399 by theronine.
Discussion
Recent studies have reported the involvement of TLRs in
the innate immune response against MAP [41,42]. Myco-
bacterial cell wall components like lipomannan, lipoara-
binomannan, phosphatidylinositol dimannoside and a
19-kDa lipoprotein are the agonists for the TLR1 and
TLR2 receptors [21,43-45], while TLR4 recognizes live M.
tuberculosis  [46]. TLRs mediated downstream pathway
leads to the up-regulation of interleukins, chemokines,
costimulatory molecules, adhesions and pro-inflamma-
tory/anti-inflammatory cytokines [47,48]. Activation of
TLRs not only direct the phagocytic cells to process and
present the antigens but also induce their self expression
[47]. TLR dependent activation of macrophages leads to
the phagocytosis and secretion of inflammatory modula-
Activation of TLRs in the mutant and wild type (WT) moDCs challenged with LPS or MAP whole cell lysate Figure 1
Activation of TLRs in the mutant and wild type (WT) moDCs challenged with LPS or MAP whole cell lysate. 
Relative fold expressions of TLR mRNA in unstimulated (dark bars) and activated mutant as well as wild type moDCs. The cells 
were either activated by LPS (shaded bars) or MAP whole cell lysate (white bars).BMC Genetics 2009, 10:21 http://www.biomedcentral.com/1471-2156/10/21
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Expression of cytokine mRNA in the activated mutant and wild type moDCs Figure 2
Expression of cytokine mRNA in the activated mutant and wild type moDCs. Comparative relative fold expressions 
of cytokine mRNA in unstimulated (dark horizontal bars) and activated mutant and wild type moDCs. The cells were either 
activated by LPS (shaded horizontal bars) or MAP whole cell lysate (white horizontal bars). -actin served as a control gene. 
Significant difference in the cytokine mRNA expression between stimulated WT and mutant moDCs is depicted by – * (p < 
0.05).BMC Genetics 2009, 10:21 http://www.biomedcentral.com/1471-2156/10/21
Page 6 of 11
(page number not for citation purposes)
tors, whereas activated dendritic cells are directed towards
the uptake, its processing and presentation of the antigen
to T cells [49].
The heterozygous variant may give ambiguous results.
Neither the hyporesponsiveness, nor the reduced cytokine
response to TLR agonists was observed in heterozygous
TLR4-Asp299Gly [50-52] and heterozygous TLR2-
Arg753Gln cells [15,33-35]. Hence, in the present study
the in vitro challenging was carried out only in moDCs car-
rying mutations in homozygous state.
In this study, IL-12, IFN- and IL-10 were expressed abun-
dantly in the activated wild type moDCs. Others [47,49]
have reported that moDCs primarily produce IL-12 upon
triggering by the TLR agonists, while macrophages pro-
duce IL-10. However, we found no significant difference
between the expression levels of IL-12 and IL-10 mRNAs
Comparative amino acid sequences of human and sheep LRR motifs of TLR1 and TLR4 Figure 3
Comparative amino acid sequences of human and sheep LRR motifs of TLR1 and TLR4. A (TLR1) and B (TLR4). 
Irregularities in the LRR motifs (LxxLxLxxNxL) are depicted with underlined letters; differences between human and ovine 
LRR domains are indicated with the dark ovals and mutations TLR1- Ser150Gly and Val220Met are highlighted with the dark 
squares. Known mutations in human TLR4 – Asp299Gly and Thr399Ile are located in extra LRR motif (*, B).BMC Genetics 2009, 10:21 http://www.biomedcentral.com/1471-2156/10/21
Page 7 of 11
(page number not for citation purposes)
in the activated wild type moDCs. In line with the previ-
ous reports [47,53] we also found mixed Th1/Th2
cytokine response in moDCs to TLR agonists. IL-12 and
IFN- are the Th1 cytokines while IL-10 belongs to the Th2
class. IL-4 was the least expressed Th2 interleukin in the
activated wild type as well as in mutant moDCs in this
study. Earlier reports [54,55] suggest the structural and
functional similarities between IL-13 and IL-4. The lowest
expression of IL-4 may be because of its substitution by IL-
13. It is important to note that IL-8 mRNA expression was
significantly hindered in the activated mutant moDCs
possessing TLR2 Leu670 mutation, but not in the acti-
vated mutant moDCs carrying TLR1 mutations. This indi-
cates that IL-8 expression might be TLR2 dependent.
Supportive data was published earlier, wherein micro-
cocci and peptidoglycan induced transcription of IL-8 in
the cells expressing TLR2 only [56].
Human and ovine TLR1 ECD consist of 20 predicted LRRs
that take part in the mycobacterial PAMP recognition
[57]. The central region of the extracellular domain of
human TLR1 (LRR9 to LRR12) is necessary for the sensing
of bacterial lipopeptides [32]. We (unpublished data,
bovine TLR1 LRR motif analysis) and others (human
TLR1) [51] have found that the central part of TLR1 ECD
(LRR9 to LRR11) is more irregular and prone to missense
mutations. In this study, novel mutation Val220Met was
observed in LRR10 motif at the 9th amino acid position
(Figure 3A). The presence of methionine in this position
may disrupt hydrogen bonds in the LRR loop structure
that may cause reduced recognition of PAMPs [51]. The
association between mutation at 9th amino acid position
in the human TLR-LRR motif and poorly-differentiated
gastric adenocarcinomas was reported recently [58]. The
increased incidence of MAP infection in sheep bearing
Val220Met mutation (43.2%; OR – 9.08) was also
observed in this study. Significant reduction (P < 0.05,
Figure 2) in the cytokine response to TLR1 agonists (LPS
and MAP lysate) in moDCs carrying 220Met (LRR10) and
150Gly (two residues upstream to LRR8) confirms the
adverse effect of mutations in the central ECD of TLR1.
In the case of TLR2, the TIR domain is crucial as it forms a
TIR-TIR dimerized platform (TLR1-TLR2 and TLR2-TLR6),
which promote homotypic protein-protein interactions
and further downstream signaling [59]. Hindered expres-
sion of the IFN-, IL-8 and IL-12 in the moDCs carrying
homozygous 670Leu (Figure 2 panel B, D and E) can be
due to the impaired dimerization of TLR2-TIR domain
with its counterparts. Similar impediment in the IL-12, IL-
8 and IFN- production was reported earlier in Arg677Trp
or Arg753Gln mutants [59-65]. Other crucial residues in
human TLR2-TIR domain (713Ser, 730Asp, 748Arg,
749Phe and 752Leu) were reported previously [61].
Mutations in the extra-LRR region may also impede the
pattern recognition. 3D structure of the TLR ECD has
demonstrated that LRR forms a loop and the juxtaposition
of several loops produce solenoid-like structure [51]. The
LRR consensus motif forms the inner core of horseshoe
structured ECD, while extra LRR regions forms convex sur-
face. Irregularities and/or mutations in the convex surface,
for example mutation in 4th residue downstream from
LRR motif, may affect PAMP binding onto the TLR horse-
shoe. The well known human TLR4 mutation, Asp299Gly,
is one of the best examples of the mutation at 4th residue
downstream from LRR11 (Figure 3B).
Conclusion
Ser150Gly and Val220Met mutations in TLR1, and
Phe670Leu in TLR2 gene were found to cause hindrance
in mycobacterial PAMPs recognition. These novel muta-
tions found in TLRs may pose a risk that increases the sus-
ceptibility to mycobacterial infection.
Methods
Animals
720 pure bred Tsigai sheep, either healthy (healthy
cohort) or showing clinical symptoms of paratuberculosis
(diseased cohort) were included in this study. The genetic
diversity, population structure of this breed is described in
details recently [66]. The sheep were from four farms
located in the same geographic area (eastern Slovakia).
These farms were chosen for the present study because of
the high incidence (10–18%) of MAP recorded during
paratuberculosis surveillance in the years 2004–2006
(unpublished data). Animals with weight loss and/or
chronic diarrhea formed a cohort suspected of paratuber-
culosis. At least 7 – 8 apparently healthy animals that had
close contact with suspected animals were also included
in the study. In this way we assured the equal probability
of MAP infection on the studied animals. The animal his-
tory was recorded and 5–10 ml of the blood (in duplicate)
was collected for the serum and buffy coat separation.
Detection of MAP
Animals were screened for the presence of anti-MAP anti-
bodies in serum as well as for the presence of IS900 ele-
ment of MAP in the buffy coat. Antibodies were detected
with Pourquier ELISA paratuberculosis kit (Institute Pour-
quier, France, http://www.institut-pourquier.fr).  IS900
based nested PCR for MAP detection was designed as
described previously [67]. The method, sensitivity and
specificity of IS900 based PCR are discussed in detail in
our previous work [67]. On the basis of PCR and ELISA
results, animals were grouped into MAP positive and neg-
ative cohorts, and cohorts were subjected to mutation
detection in TLR genes.BMC Genetics 2009, 10:21 http://www.biomedcentral.com/1471-2156/10/21
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Construction of primers and PCR for amplification of TLR 
gene fragments
ECD of the TLR1 was targeted for mutation detection.
Primers were designed (DNASTAR) to amplify a gene frag-
ment covering LRR8 to LRR11 (Table 4). Conditions for
PCR were: initial denaturation at 95°C for 3 min, fol-
lowed by 35 cycles of 94°C for 1.0 min, 52°C for 1 min
20 sec, 72°C for 1.0 min with final extension at 72°C for
10 min. Primers for TLR2 were constructed to amplify
gene fragments covering earlier reported Pro681His,
Arg677Trp and Arg753Gln mutations [15,39] located in
Toll/Interleukin-1 receptor (TIR) domain. Primers
designed for TLR4 spanned both previously described
major polymorphism sites, Asp299Gly and Thr399Ile
[40] located in ECD (LRR11 to LRR16). Nucleotide
sequences of TLR2 and TLR4 primers are depicted in Table
4. PCR conditions for TLR2 gene were: initial denatura-
tion at 94°C for 3 min, followed by 35 cycles of 94°C for
60 sec, 56°C for 45 sec, and 72°C for 60 sec with final
extension at 72°C for 10 min. The cycling conditions for
TLR4 were similar to TLR2 except annealing temperature
(57°C).
Single strand conformational polymorphism analysis 
(SSCP)
Briefly, 5 l of amplified product was mixed with equal
amount of loading dye (98% formamide, 10 mM EDTA,
0.025% bromophenol blue, 0.025% xylene-cyanol), sub-
jected to denaturation at 95°C for 10 min and then
cooled rapidly on ice. Denatured single-stranded amplim-
ers were loaded onto 6% acrylamide/bisacrylamide
(37.5:1, v/v; Bio-Rad) gels. Electrophoresis was performed
using 200 V at 8°C in 0.5% TBE buffer for 20 hours in the
electrophoresis chamber (Ingeny, The Netherlands). Gels
were silver-stained. Samples were grouped based on SSCP
profiles by using Gel-Scan software (BioSciTec, Germany).
DNA Sequencing
Representative samples from each SSCP genotype were
sequenced on an Avant3100 sequencer (Applied Biosys-
tem). The sequences were aligned, then checked for muta-
tions and validated using SeqScape v.2.1 software
(Applied Biosystem). Sequences were submitted to the
GeneBank (USA) under the accession numbers EF681961
to EF681970. The SNPs were submitted to dbSNP
(Genebank) database under the accession numbers:
76880840 to 76880850 and 76878648 to 76878669.
In-vitro treatment of moDCs with LPS or MAP whole cell 
lysate
Representative sheep (n = 6 per mutation) which were not
infected with MAP but carrying mutations associated with
MAP infection in the homozygous state (depicted in
tables 1, 2, 3) were included in this phase of the study.
Healthy subjects (n = 6) without mutations in TLR were
served as controls. moDCs were generated from periph-
eral blood mononuclear cells as described previously [47]
in Nunc 6-well tissue culture plates (approximately 5 ×
105 cells/well in 2 ml of cell suspension). moDCs were
either treated with 100 l of LPS (1 g/ml; Sigma) or 100 l
of MAP whole cell lysate (~890 g/ml of protein concen-
tration). As a negative control (no cell activation) moDCs
were kept untreated. Cells were incubated at 37°C for 4 h
in 5% CO2 incubator, washed and total RNA was extracted
Table 4: Primers used in this study
Gene Sequence (5'-3') Amplicon length (bp) Annealing temperature (°C)
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using Purezol RNA isolation kit (Bio-Rad). Complemen-
tary DNA (cDNA) was synthesized by using iScript cDNA
synthesis kit (Bio-Rad). The cDNA was used for real time
PCR to examine the effect of treatment of moDCs on
cytokine and TLR mRNA expression. moDCs with or with-
out mutations are designated as mutant moDCs and
wildtype moDCs respectively in this report.
Real time PCR for quantification of TLRs and cytokines 
mRNA expression
Primers used to amplify cDNAs of the TLRs, cytokines as
well as housekeeping gene are depicted in the Table 4.
PCR reactions were carried out in triplicate by using iQ
SYBR green super mix Kit (Bio-Rad). All PCRs were fol-
lowed by melting curve analysis (iQ5 thermocycler, Bio-
Rad). Melting curve analysis was used to confirm the
amplified product purity (confirmation of no non-spe-
cific amplicons). For the comparison of gene expression
the Ct method (relative quantity gene expression) was
applied using iQ5 software (Bio-Rad).
In silico ovine LRR motif analysis
The ovine TLR nucleotide sequences obtained in this
study were aligned by ClustalW multiple alignment
method (DNASTAR software), translated into putative
amino acids and consensus sequences were obtained
(BioEdit software). LRR motifs were outlined according to
the method described earlier [68] using PFAM and
SSpro4.0 servers [69].
Statistical analysis
The possible linkage between mutation and increased
MAP infection was calculated by Odd's ratio (OR) (Win-
episcope software). Relative quantity gene expression
(Ct) was determined as follows -
Where E = efficiency of primer set (% efficiency * 0.01+1),
Ct(control)  = Average Ct for control, and Ct(sample)  =
Average Ct for the sample. Paired t-test (STATGRAPHICS
plus 5.1) was used to assess the mutation as well as stim-
ulant (MAP lysate or LPS) dependent variations in
cytokine mRNA expression.
Ethical approval for the use of animals in this study
Although animals were used in this experimental work,
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